NextCure Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
NXTC$5.98-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
(in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Assets · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $13,082 | | $26,630 | ||
| Marketable securities | | | 95,217 | | | 133,281 |
| Prepaid expenses and other current assets | | 4,426 | | 4,072 | ||
| Total current assets | | 112,725 | | 163,983 | ||
| Property and equipment, net | | 9,033 | | 11,897 | ||
| Right of use assets | | | 4,398 | | | 5,016 |
| Other assets | | 1,882 | | 3,265 | ||
| Total assets | | $128,038 | | $184,161 | ||
| Liabilities and Stockholders’ Equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $2,330 | | $4,270 | ||
| Accrued liabilities and other liabilities | | 4,553 | | 4,857 | ||
| Total current liabilities | | 6,883 | | 9,127 | ||
| Lease liabilities, long term | | | 5,949 | | | 6,605 |
| Other long-term liabilities | | 785 | | 899 | ||
| Total liabilities | | 13,617 | | 16,631 | ||
| Stockholders’ equity: | | | ||||
| Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; No shares issued and outstanding at December 31, 2023 and December 31, 2022 | | | — | | | — |
| Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022; 27,903,027 and 27,774,536 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | | 28 | | 28 | ||
| Additional paid-in capital | | 439,097 | | 430,755 | ||
| Accumulated other comprehensive loss | | | (222) | | | (1,494) |
| Accumulated deficit | | (324,482) | | (261,759) | ||
| Total stockholders’ equity | | 114,421 | | 167,530 | ||
| Total liabilities and stockholders’ equity | | $128,038 | | $184,161 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.